As biologics, biomarker-enriched trials and real-world evidence reshape the COPD landscape, sponsors face both new opportunities and increasing complexity. Success depends on translating these advances into effective cli...
Biotech
Developing transformative therapies with small & mid-sized biopharma companies requires a flexible approach
PlayFrom here to where?
Plotting a course to bring APAC-developed drugs to the world
Download Global and China biotech survey reports
Two new survey reports of 260+ Global and China-based biotech leaders are ready to download.
Driving biotech success at every milestone
Biotech companies are pioneering the future of medicine from genomic breakthroughs to first-in-class immunotherapies. With focused pipelines and bold ambitions, many biotechs operate without the full infrastructure of larger organizations, making speed, precision, and strategic support essential.
ICON delivers the expertise, technology, and global reach to turn biotech innovation into impact. Our empowered structure enables fast decision-making and flexible engagement, backed by the scale of one of the world’s most innovative CROs.
Our dedicated biotech teams are built to understand your unique pressures and priorities, collaborating closely, sharing ownership, and delivering results at every stage of development.
Our four-pillar approach, Patients, People, Process, and Partnership, is designed to transform biotech ambition into real-world impact. By combining patient-centric strategies, expert talent, streamlined operations, and collaborative engagement, ICON empowers you to deliver life-changing therapies faster.
Emerging biotech funding
As new funding models and investor priorities reshape the biotech landscape, companies must navigate a dynamic environment with agility and foresight to secure the capital needed for innovation.
Behind Biotech
Our experts bring more than scientific knowledge - they bring purpose, perspective, and a commitment to partnership.
Partnering with biotechs to transform ideas into life-changing therapies.
ICON provides end-to-end capabilities, from early-phase design to market access; ensuring agility, scalability, and scientific excellence throughout the development journey.
-
Тailored clinical development
8,000 professionals dedicated to biotech delivering agile, customized solutions built around your needs.
-
Consulting and advisory services
Strategic guidance from early development through to commercialization.
-
Therapeutic expertise
Deep experience across therapeutic areas, from first-in-human to late-phase trials.
-
Tools and technologies
Innovative platforms that accelerate research and enhance data-driven decisions.
Emerging biotech, empowered for investment
ICON partners with biotech innovators to sharpen funding strategies, align with investor expectations, and drive value across every stage of development.
Optimising biotech funding whitepaper series
In this two-part whitepaper series on biotech funding, we firstly share insights on how biotechs can secure funding in a highly competitive market, and then shed light on the opportunities available to utilise these funds more effectively and efficiently.
Early phase challenges for biotechs
This whitepaper explores the growing challenges facing biotech during early phase drug development, and how these can be navigated to ensure the best possible outcomes.
Case studies
Explore our biotech case study library showcasing real-world success stories where bold ambition meets ICON’s expertise.
Empowering biotech innovation at every stage of development.
Through advanced analytics, global trial expertise, and strategic partnerships, ICON enables biotechs to streamline processes and achieve faster, smarter outcomes.
Early, precise and efficient
The methods and technologies advancing Alzheimer’s and Parkinson’s R&D
In this CNS whitepaper, which includes extracts from our survey of over 120 neurodegenerative therapeutic developers, we examine how innovative methodologies and technologies are being implemented to improve the success rate of clinical trials across a range of neurodegenerative disorders.
Procedural and regulatory know-how for China biotech in the EU
How to navigate EU MAA regulations and registration
Learn how to navigate the European Medicines Agency registration and regulation procedures and gain access to a potential patient pool of 500 million people.
2023 biotech sector survey
The biotech industry stands at a pivotal moment, navigating funding challenges with resilience and adaptability. After a period of remarkable growth and investment, the landscape shifted abruptly in 2022, and 2023 continued to present its own set of challenges.
De-risking clinical development of precision medicines in oncology
This whitepaper reviews the most pressing challenges and opportunities facing the oncology therapeutic landscape in the emerging era of precision medicine, and reports on how those opportunities and challenges vary by organisational size and region.
Digital disruption
The clinical research industry is making strides in technological innovation, with small but steady increases to the percentage of companies implementing and piloting digital technologies. However, our 2024 digital disruption survey conducted with Citeline shows a slower pace of innovation than predicted by the 2019 survey. Why is this the case?
Obesity and beyond
Embracing multi-indication potential during clinical development
This whitepaper explores the strategic rise of multi-indication drug development for obesity and its comorbidities, offering insights into clinical trial design, regulatory pathways, and commercial opportunities based on recent industry trends and survey data.
.jpeg?crop=yes&w=1017&h=1017&a=325,0&itok=ZQ_TVcyw "obesity_scan_icons"){kind=icon}
Building strong foundations: regulatory insights for biotechs.
Through early engagement strategies, deep procedural expertise, and global regulatory insight, ICON equips biotechs to anticipate challenges, streamline submissions, and accelerate access to key markets worldwide.
Early engagement and regulatory considerations for biotech
Gain insight into the common questions small and emerging biotech companies face, and the importance of early engagement and regulatory affairs when developing an asset and considering a drug development partner.
Biotech blogs and media contributions
-
Media article: The rising impact of biomarkers in early clinical development
Dr. Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies.
-
Media article: Partnering for success in early phase clinical development
With the average phase 1 trial costing millions of dollars and consuming valuable time, biotechs have little room for error. This article discusses how partnering with a CRO can benefit a small biotech - helping to fill the gaps in knowledge, resources infrastructure.
-
Media article: Precision Medicine: Pitfalls and Potential
In this article, Anna Guildford, Senior Principal, Medical Writing, shares insights on how precision medicine is discussed as a novel approach using genetic and health data to tailor treatments, improving patient outcomes and reducing adverse effects.
-
Blog: Investigating multi-indication drug targets
This blog will explore some of the multi-indication drug targets that have already been developed in multiple applications, as well as considerations for entering clinical trials, such as building evidence and trial design.
-
Blog: Navigating early phase challenges for biotechs
To better understand the concerns of biotechs in early phases, ICON conducted a survey of 149 professionals representing small- and medium-sized biotech organisations from North America and Europe.
-
Blog: The benefits of going big: why small biotechs need large CRO partners
Small biotech companies can gain significant benefits by partnering with a big CRO – if it’s the right fit. We outline some of the benefits of strategic partnerships for cash-constrained biotech.
-
Media article: Building on biotech confidence with strategic R&D
In this article Dr. Chris Smyth, President of ICON Biotech outlines how biotech companies can build on growing market confidence by utilising their capital in the most effective and efficient way possible.
-
Media article: US Pharma and Biotech Summit 2024: Evolving clinical research
In this news article, Applied Clinical Trials reports on ICON CEO Steve Cutler’s discussion at the FT US Pharma and Biotech Summit.
Start the conversation
Start the conversation with our biotech team to explore how ICON can accelerate your clinical development and deliver investor-ready trial strategies tailored to your goals.
